Luspatercept (sold as Reblozyl) has shown promising results for certain people with MDS, particularly those with a subtype called MDS with ring sideroblasts (MDS-RS).
In clinical trials, people who took luspatercept were more likely to no longer need regular blood transfusions compared to those who didn't take the drug Show Full Answer
Luspatercept (sold as Reblozyl) has shown promising results for certain people with MDS, particularly those with a subtype called MDS with ring sideroblasts (MDS-RS).
In clinical trials, people who took luspatercept were more likely to no longer need regular blood transfusions compared to those who didn't take the drug. This is a meaningful outcome, since frequent transfusions can lead to long-term health complications. It's worth noting that luspatercept is FDA-approved specifically for people who meet these criteria:
- Diagnosed with MDS-RS or a related subtype
- Have very low-, low-, or intermediate-risk disease
- Have already tried an erythropoiesis-stimulating agent without success
- Have needed red blood cell transfusions in the past eight weeks
If any of those boxes don't apply, it may not be the right fit — but that's a conversation worth having with a care team to explore what options make the most sense.
AI-generated responses are not a substitute for medical advice. These services are not intended to
diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.
Treatment Advances for MDS
July 31
Join
Your Privacy Choices
